In addition to its anti-tumor functions, IFN-γ also exerts an anti-osteoclastogenic effect by inducing degradation of tumor necrosis factor receptor-associated factor 6 (TRAF6), resulting in the inhibition of receptor activator of nuclear factor (NF)-kappa B ligand (RANKL) signaling9. Here, IFNG is linked to neoplasm.